Koers Starpharma Holdings Limited Other OTC
Aandelen
SPHRY
US8555631022
Farmaceutische producten
Omzet 2022 | 5,16 mln. 3,43 mln. 3,21 mln. | Omzet 2023 | 4,21 mln. 2,8 mln. 2,61 mln. | Marktkapitalisatie | 127 mln. 84,57 mln. 79,06 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -16 mln. -10,63 mln. -9,94 mln. | Nettowinst (verlies) 2023 | -15 mln. -9,97 mln. -9,32 mln. | EV/omzet 2022 | 50,5 x |
Nettoliquiditeiten 2022 | 41,73 mln. 27,73 mln. 25,92 mln. | Nettoliquiditeiten 2023 | 26,91 mln. 17,88 mln. 16,72 mln. | EV/omzet 2023 | 23,8 x |
K/w-verhouding 2022 |
-18,5
x | K/w-verhouding 2023 |
-7,75
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 92,55% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Cheryl Maley
CEO | Chief Executive Officer | - | 08/01 |
Justin Cahill
DFI | Director of Finance/CFO | - | 03-04-23 |
Tony Eglezos
PRN | Corporate Officer/Principal | - | 12-08-13 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Jeff Davies
BRD | Director/Board Member | - | 01-04-22 |
Robert Thomas
CHM | Chairman | 79 | 04-12-13 |
David McIntyre
BRD | Director/Board Member | 53 | 01-03-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+55,95% | 819 mld. | |
+43,48% | 638 mld. | |
-6,98% | 351 mld. | |
+19,08% | 329 mld. | |
+9,05% | 298 mld. | |
+17,01% | 242 mld. | |
+2,54% | 225 mld. | |
+13,16% | 217 mld. | |
+8,91% | 168 mld. |